Human IL-13 R alpha2 Biotinylated Antibody

Two type1 membrane proteins belonging to the hemopoietin receptor family have been cloned and shown to bind IL-13 with differing affinities. The lower affinity IL-13 binding protein, previously designated IL-13 R alpha, IL-13 R alpha^l or NR4, is now referred to as IL-13 R alpha1. The high affinity IL-13 binding protein, previously also designated IL-13 R or IL-13 R alpha^l, is now referred to as IL-13 R alpha2.

Human IL-13 R alpha2 was originally cloned from the Caki-1 human renal carcinoma cell line. The IL-13 R alpha2 cDNA encodes a 380 amino acid (aa) residue precursor protein with a putative 26 aa residue signal peptide, a 317 residue extracellular domain, a 20 aa residue transmembrane region and a 17 aa residue cytoplasmic tail. Human and mouse IL-13 R alpha2 share 59% aa sequence identity. The extracellular domain of IL-13 R alpha2 is also closely related to that of IL-13 R alpha1. However, the 17 aa residue cytoplasmic domain of IL-13 R alpha2 is much shorter than that of IL-13 R alpha1, suggesting that the two receptors are functionally distinct. IL-13 R alpha1 has been shown to combine with the IL-4 R to form a high-affinity receptor complex capable of transducing an IL-13-dependent proliferative signal. The role of IL-13 R alpha2 in IL-13 signaling remains to be elucidated. The amino-terminal 27 aa residues of the human and mouse IL-13 R alpha2 are nearly identical to that of a soluble mouse IL-13 binding protein purified from mouse serum and urine.